检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:刘衡 LIU Heng(Department of Critical Care Medicine,Baise City People's Hospital,Baise,Guangxi Zhuang Autoncomous Regin,533000 China)
机构地区:[1]百色市人民医院重症医学科,广西百色533000
出 处:《中外医疗》2021年第24期178-180,共3页China & Foreign Medical Treatment
摘 要:目的研究将血清降钙素原(PCT)、白细胞介素-6(IL-6)、C反应蛋白(CRP)检测应用于重症多发伤合并早期脓毒症患者中的作用与效果。方法方便选取2018年4月—2019年2月期间该院接收的重症多发伤合并早期脓毒症病例78例,作为观察组;在相同的时间段中,选取该院接收的重症多发伤没有出现脓毒症病例33例,作为对照组1;选取该院接收的健康体检者33名,作为对照组2,对全部受检对象均实施PCT、IL-6、CRP检测,比较3组的PCT、IL-6、CRP检测结果。结果观察组PCT(4.42±0.54)μg/L、IL-6(29.82±2.03)mg/L、CRP(34.55±0.87)mg/L,高于对照组1和对照组2,差异有统计学意义(t=17.653、31.463、41.726,P<0.05;t=41.192、48.026、122.860,P<0.05)。结论PCT、IL-6、CRP检测应用到重症多发伤合并早期脓毒症患者中,能够获得更为理想的效果。Objective To study the effects and effects of serum procalcitonin(PCT),interleukin-6(IL-6)and C-reactive protein(CRP)detection in patients with severe multiple injuries and early sepsis.Methods Convenientlyselected 78 cases of severe multiple injury combined with early sepsis received in the hospital from April 2018 to February 2019 and regarded as the observation group.In the same time period,selected the hospital of the 33 cases of severe multiple injuries received without sepsis were used as control group 1.33 healthy medical examiners received in the hospital were selected as control group 2.PCT and IL-6、CRP test were applied to all subjects,compared the test results of PCT,IL-6 and CRP in the 3 groups.Results The observation group PCT(4.42±0.54)μg/L,IL-6(29.82±2.03)mg/L,CRP(34.55±0.87)mg/L,compared with the control group 1,and the control group 2,the difference was statistically significant(t=17.653,31.463,41.726,P<0.05;t=41.192,48.026,122.860,P<0.05).Conclusion The application of PCT,IL-6,and CRP detection to patients with severe multiple trauma combined with early sepsis can achieve more ideal results.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.49